233 related articles for article (PubMed ID: 32593961)
1. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.
Lucchini M; Bianco A; Del Giacomo P; De Fino C; Nociti V; Mirabella M
Mult Scler Relat Disord; 2020 Sep; 44():102323. PubMed ID: 32593961
[TBL] [Abstract][Full Text] [Related]
2. Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab.
Thornton JR; Harel A
Mult Scler Relat Disord; 2020 Sep; 44():102341. PubMed ID: 32622338
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
[TBL] [Abstract][Full Text] [Related]
4. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
5. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
6. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.
Flores-Gonzalez RE; Hernandez J; Tornes L; Rammohan K; Delgado S
Mult Scler Relat Disord; 2021 Apr; 49():102777. PubMed ID: 33508573
[TBL] [Abstract][Full Text] [Related]
7. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
[TBL] [Abstract][Full Text] [Related]
9. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
10. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
11. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers.
Iannetta M; Landi D; Cola G; Malagnino V; Teti E; Fraboni D; Buccisano F; Grelli S; Coppola L; Campogiani L; Andreoni M; Marfia GA; Sarmati L
Mult Scler Relat Disord; 2021 Oct; 55():103157. PubMed ID: 34418737
[TBL] [Abstract][Full Text] [Related]
12. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
13. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
[TBL] [Abstract][Full Text] [Related]
14. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic.
Meca-Lallana V; Aguirre C; Cardeñoso L; Alarcon T; Figuerola-Tejerina A; Del Río B; Álvarez MR; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102244. PubMed ID: 32544863
[No Abstract] [Full Text] [Related]
16. COVID-19 will change MS care forever - No.
Preziosa P; Rocca MA; Filippi M
Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
[No Abstract] [Full Text] [Related]
17. Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.
Mado H; Kubicka-Bączyk K; Adamczyk-Sowa M
J Int Med Res; 2021 Sep; 49(9):3000605211044378. PubMed ID: 34528472
[TBL] [Abstract][Full Text] [Related]
18. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
[No Abstract] [Full Text] [Related]
19. SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic.
Canetti D; Dell'Acqua R; Riccardi N; Della Torre L; Bigoloni A; Muccini C; Bruzzesi E; Ranzenigo M; Chiurlo M; Racca S; Galli C; Castagna A; Tambussi G; Lazzarin A
New Microbiol; 2020 Oct; 43(4):161-165. PubMed ID: 33135083
[TBL] [Abstract][Full Text] [Related]
20. Immunochromatographic test for differentiation detection of IgM and IgG to SARS-CoV-2.
Akinshina YA; Mardanly SS; Kiseleva VA
Klin Lab Diagn; 2020 Dec; 65(11):688-692. PubMed ID: 33301658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
